236 related articles for article (PubMed ID: 29076241)
1. Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours.
Hwang CC; Igase M; Sakurai M; Haraguchi T; Tani K; Itamoto K; Shimokawa T; Nakaichi M; Nemoto Y; Noguchi S; Coffey M; Okuda M; Mizuno T
Vet Comp Oncol; 2018 Jun; 16(2):229-238. PubMed ID: 29076241
[TBL] [Abstract][Full Text] [Related]
2. The effects of oncolytic reovirus in canine lymphoma cell lines.
Hwang CC; Umeki S; Igase M; Coffey M; Noguchi S; Okuda M; Mizuno T
Vet Comp Oncol; 2016 Aug; 14 Suppl 1():61-73. PubMed ID: 25319493
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.
Roulstone V; Khan K; Pandha HS; Rudman S; Coffey M; Gill GM; Melcher AA; Vile R; Harrington KJ; de Bono J; Spicer J
Clin Cancer Res; 2015 Mar; 21(6):1305-12. PubMed ID: 25424857
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumour activity of oncolytic reovirus against canine histiocytic sarcoma cells.
Igase M; Shousu K; Fujiki N; Sakurai M; Bonkobara M; Hwang CC; Coffey M; Noguchi S; Nemoto Y; Mizuno T
Vet Comp Oncol; 2019 Jun; 17(2):184-193. PubMed ID: 30761736
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.
Ilett EJ; Prestwich RJ; Kottke T; Errington F; Thompson JM; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Vile RG; Melcher AA
Gene Ther; 2009 May; 16(5):689-99. PubMed ID: 19282847
[TBL] [Abstract][Full Text] [Related]
6. The oncolytic effects of reovirus in canine solid tumor cell lines.
Igase M; Hwang CC; Coffey M; Okuda M; Noguchi S; Mizuno T
J Vet Med Sci; 2015 May; 77(5):541-8. PubMed ID: 25648933
[TBL] [Abstract][Full Text] [Related]
7. Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.
LeBlanc AK; Naik S; Galyon GD; Jenks N; Steele M; Peng KW; Federspiel MJ; Donnell R; Russell SJ
Hum Gene Ther Clin Dev; 2013 Dec; 24(4):174-81. PubMed ID: 24219832
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.
Forsyth P; Roldán G; George D; Wallace C; Palmer CA; Morris D; Cairncross G; Matthews MV; Markert J; Gillespie Y; Coffey M; Thompson B; Hamilton M
Mol Ther; 2008 Mar; 16(3):627-32. PubMed ID: 18253152
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumor.
Igase M; Hwang CC; Kambayashi S; Kubo M; Coffey M; Miyama TS; Baba K; Okuda M; Noguchi S; Mizuno T
Can J Vet Res; 2016 Jan; 80(1):21-31. PubMed ID: 26733729
[TBL] [Abstract][Full Text] [Related]
10. The potential of the combined use of targeted type I interferon pathway inhibitors and oncolytic viruses to treat sarcomas.
MacNeill AL
Vet Comp Oncol; 2020 Mar; 18(1):36-42. PubMed ID: 31618515
[TBL] [Abstract][Full Text] [Related]
11. Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma.
Lawson KA; Mostafa AA; Shi ZQ; Spurrell J; Chen W; Kawakami J; Gratton K; Thakur S; Morris DG
Clin Cancer Res; 2016 Dec; 22(23):5839-5850. PubMed ID: 27220962
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.
Vidal L; Pandha HS; Yap TA; White CL; Twigger K; Vile RG; Melcher A; Coffey M; Harrington KJ; DeBono JS
Clin Cancer Res; 2008 Nov; 14(21):7127-37. PubMed ID: 18981012
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumour activity of oncolytic Western Reserve vaccinia viruses in canine tumour cell lines, xenografts, and fresh tumour biopsies.
Autio K; Knuuttila A; Kipar A; Ahonen M; Parviainen S; Diaconu I; Kanerva A; Hakonen T; Vähä-Koskela M; Hemminki A
Vet Comp Oncol; 2016 Dec; 14(4):395-408. PubMed ID: 25302859
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic viral therapy using reovirus.
Thirukkumaran C; Morris DG
Methods Mol Biol; 2009; 542():607-34. PubMed ID: 19565924
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic reovirus in canine mast cell tumor.
Hwang CC; Umeki S; Kubo M; Hayashi T; Shimoda H; Mochizuki M; Maeda K; Baba K; Hiraoka H; Coffey M; Okuda M; Mizuno T
PLoS One; 2013; 8(9):e73555. PubMed ID: 24073198
[TBL] [Abstract][Full Text] [Related]
16. Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.
Ilett E; Kottke T; Thompson J; Rajani K; Zaidi S; Evgin L; Coffey M; Ralph C; Diaz R; Pandha H; Harrington K; Selby P; Bram R; Melcher A; Vile R
Gene Ther; 2017 Jan; 24(1):21-30. PubMed ID: 27779616
[TBL] [Abstract][Full Text] [Related]
17. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.
Ilett EJ; Bárcena M; Errington-Mais F; Griffin S; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Limpens RW; Mommaas M; Hoeben RC; Vile RG; Melcher AA
Clin Cancer Res; 2011 May; 17(9):2767-76. PubMed ID: 21389099
[TBL] [Abstract][Full Text] [Related]
18. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
Wouda RM; Hocker SE; Higginbotham ML
Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
[TBL] [Abstract][Full Text] [Related]
19. Seroepidemiology of reovirus in healthy dogs in six prefectures in Japan.
Hwang CC; Mochizuki M; Maeda K; Okuda M; Mizuno T
J Vet Med Sci; 2014 Mar; 76(3):471-5. PubMed ID: 24284973
[TBL] [Abstract][Full Text] [Related]
20. Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer.
Naik S; Galyon GD; Jenks NJ; Steele MB; Miller AC; Allstadt SD; Suksanpaisan L; Peng KW; Federspiel MJ; Russell SJ; LeBlanc AK
Mol Cancer Ther; 2018 Jan; 17(1):316-326. PubMed ID: 29158470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]